References
- Fricker SP. Physiology and pharmacology of plerixafor. Transfus Med Hemother 2013;40:237–45
- Dhakal B, Strouse C, D’Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, et al. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. Biol Blood Marrow Transplant 2014;20:1926–31
- Lee SY, Sanchorawala V, Seldin DC, Mark Sloan J, Andrea N, Quillen K. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Amyloid 2014;21:149–53
- Kaul E, Shah G, Chaulagain C, Comenzo RL. Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis. Bone Marrow Transplant 2014;49:1233
- Aubrey-Bassler FK, Sowers N. 613 cases of splenic rupture without risk factors or previously diagnosed disease: a systematic review. BMC Emerg Med 2012;12:11
- Palladini G, Dispenzieri A, Gertz MA, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–9
- Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–7
- Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on amyloid and amyloidosis. Am J Hematol 2005;79:319–28